AU5287596A - Cancerous metastasis inhibitor - Google Patents

Cancerous metastasis inhibitor

Info

Publication number
AU5287596A
AU5287596A AU52875/96A AU5287596A AU5287596A AU 5287596 A AU5287596 A AU 5287596A AU 52875/96 A AU52875/96 A AU 52875/96A AU 5287596 A AU5287596 A AU 5287596A AU 5287596 A AU5287596 A AU 5287596A
Authority
AU
Australia
Prior art keywords
cancerous metastasis
benzoic acid
metastasis inhibitor
cancerous
coch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU52875/96A
Other versions
AU693682B2 (en
Inventor
Koji Murakami
Jiro Shibata
Koichi Shudo
Konstanty Wierzba
Yuji Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of AU5287596A publication Critical patent/AU5287596A/en
Application granted granted Critical
Publication of AU693682B2 publication Critical patent/AU693682B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A cancerous metastasis inhibitor containing a benzoic acid derivative which is represented by general formula (I) and has a remarkably excellent cancerous metastasis inhibitory effect as the active ingredient; the use of the benzoic acid derivatives for producing the cancerous metastasis inhibitor; and a method of inhibiting cancerous metastasis by administering an effective amount of the benzoic acid derivative to mammals. In said formula (I), R1, R2, R3 and R4 may be the same or different and each represents hydrogen, hydroxy or trimethylsilyl, or alternatively R3 and R4 are bonded to each other to represent lower alkyl-substituted tetramethylene; and X represents -COCH=C(OH)-, -NHCO-or -CONH-, provided when R3 and R4 are bonded to each other to represent lower alkyl-substituted tetramethylene, X represents -COCH=C(OH)- or -CONH-.
AU52875/96A 1995-04-10 1996-04-10 Cancerous metastasis inhibitor Ceased AU693682B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP8380395 1995-04-10
JP7-83803 1995-04-10
PCT/JP1996/000980 WO1996032101A1 (en) 1995-04-10 1996-04-10 Cancerous metastasis inhibitor

Publications (2)

Publication Number Publication Date
AU5287596A true AU5287596A (en) 1996-10-30
AU693682B2 AU693682B2 (en) 1998-07-02

Family

ID=13812829

Family Applications (1)

Application Number Title Priority Date Filing Date
AU52875/96A Ceased AU693682B2 (en) 1995-04-10 1996-04-10 Cancerous metastasis inhibitor

Country Status (12)

Country Link
US (1) US5750515A (en)
EP (1) EP0768084B1 (en)
JP (1) JP3208437B2 (en)
KR (1) KR100207356B1 (en)
AT (1) ATE223713T1 (en)
AU (1) AU693682B2 (en)
CA (1) CA2191850C (en)
DE (1) DE69623555T2 (en)
DK (1) DK0768084T3 (en)
ES (1) ES2180751T3 (en)
PT (1) PT768084E (en)
WO (1) WO1996032101A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008204A (en) 1995-09-01 1999-12-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
KR20010063274A (en) * 1999-12-22 2001-07-09 성재갑 Pharmaceutical composition containing [1-{[1-(1,3-benzodioxol-5-ylmethyl)-1H-imidazol-5-yl] methyl}-4-(1-naphthyl)-1H-pyrrol-3-yl](4-methyl-1-piperazinyl)methanone for anticancer agent
NO20003591L (en) * 2000-07-13 2002-01-14 Thia Medica As Fatty acid analogues for the treatment of cancer
BRPI0114344B8 (en) 2000-10-02 2021-05-25 Hoffmann La Roche retinoid compound, its use, its pharmaceutical composition and its preparation process
US8198328B2 (en) 2004-01-21 2012-06-12 New York University Treatment of cancer using benzoic acid derivatives
US20050202055A1 (en) * 2004-03-11 2005-09-15 Koichi Shudo, Tokyo, Japan Anti-wrinkle agent
US8415315B2 (en) 2004-05-06 2013-04-09 University Of Central Florida Research Foundation, Inc. Methods and compositions for inhibiting the proliferation of cancer cells
US20080275002A1 (en) * 2005-03-08 2008-11-06 Taiho Pharmaceutical Co., Ltd. Method for Treatment of Hepatic Cancer
CA2626879A1 (en) * 2005-10-24 2007-05-03 Taiho Pharmaceutical Co., Ltd. Method for predicting efficacy of rar-.alpha. agonist
TW200922554A (en) * 2007-10-11 2009-06-01 Taiho Pharmaceutical Co Ltd Bis(trimethylsilyl)phenyl compound or salt thereof, and use thereof
GB0915196D0 (en) 2009-09-01 2009-10-07 King S College London Therapeutic compounds and their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5513238A (en) * 1978-07-17 1980-01-30 Banyu Pharmaceut Co Ltd Novel compound having immunoactivating action, its preparation and application
JP2752630B2 (en) * 1988-03-29 1998-05-18 大鵬薬品工業株式会社 New benzoic acid derivative and method for producing the same
JP2761023B2 (en) * 1989-03-20 1998-06-04 大鵬薬品工業株式会社 New benzoic acid derivative and method for producing the same
JPH0366647A (en) * 1989-08-03 1991-03-22 Koichi Shudo Phenyl benzoate derivative
JPH03115289A (en) * 1989-09-28 1991-05-16 Koichi Shudo Novel benzoic acid derivative, production of same derivative and use thereof
JP3650144B2 (en) * 1994-06-08 2005-05-18 花王株式会社 Cell adhesion inhibitor

Also Published As

Publication number Publication date
AU693682B2 (en) 1998-07-02
ATE223713T1 (en) 2002-09-15
WO1996032101A1 (en) 1996-10-17
KR100207356B1 (en) 1999-07-15
DE69623555D1 (en) 2002-10-17
PT768084E (en) 2002-12-31
KR970703761A (en) 1997-08-09
US5750515A (en) 1998-05-12
EP0768084A4 (en) 1999-05-06
EP0768084A1 (en) 1997-04-16
DE69623555T2 (en) 2003-05-15
CA2191850A1 (en) 1996-10-17
DK0768084T3 (en) 2002-10-14
JP3208437B2 (en) 2001-09-10
CA2191850C (en) 2002-06-18
ES2180751T3 (en) 2003-02-16
EP0768084B1 (en) 2002-09-11

Similar Documents

Publication Publication Date Title
EP0513387A4 (en) Active oxygen inhibitor
AU7125291A (en) Inhibitors of nitric oxide biosynthesis
AU2003222450A1 (en) Stabilized ascorbic acid derivatives
AU693682B2 (en) Cancerous metastasis inhibitor
MY113732A (en) Arylthio compounds
MY115307A (en) Preparation for epidermis
AU591860B2 (en) Pyrolidineamide derivative having anti-prolyl endopeptidase
AU3559193A (en) New 3',5'-di-tert-butyl-4'-hydroxy flavones, process for the preparation thereof and pharmaceutical compositions containing them
AU7263591A (en) Benzisothiazolinone-1-dioxide derivatives as elastase inhibitors
WO2005046672A3 (en) Use of glucosidase inhibitors for therapy of mucovisidosis
UA49884C2 (en) a-hydro-carboxylic acid derivatives and their use as medicaments
EP0786252A4 (en) Antitumor agent
EP0292576A4 (en) Anti-ulcerous agent containing chalcone derivative as effective ingredient and novel chalcone derivatives
EP0757987A4 (en) Pyrazolecarboxylic acid derivative and plant disease control agent
BG104034A (en) Method for the preparation of pharmaceutical compounds of antidepressive effect and against the parkinson syndrome effect
AU6306190A (en) Novel substituted alkyl piperidines and their use as inhibitors of cholesterol synthesis
CA2076772A1 (en) Novel vitamin d3 analogues
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
EP0605728A4 (en) Chromone derivative and aldose reductase inhibitor containing the same as active ingredient.
EP0790247A4 (en) Tetrahydroisoquinoline derivative and medicinal preparation containing the same
EP0414903A4 (en) New thioproline derivative
SE9802546D0 (en) Medicinal product and method for treatment and prevention of dyskinesia
NO994107D0 (en) Preparations for the treatment or prevention of prostate cancer
HUT75124A (en) Use of bicyclolactam derivatives for producing pharmaceutical compositions having anxiolytic activity
ES2177623T3 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING CEFTRIAXONE AND PENEMS.